Literature DB >> 29129756

Assessment of Oncological Outcomes After Radical Prostatectomy According to Preoperative and Postoperative Cancer of the Prostate Risk Assessment Scores: Results from a Large, Two-center Experience.

Sami-Ramzi Leyh-Bannurah1, Paolo Dell'Oglio2, Emanuele Zaffuto2, Alberto Briganti2, Jonas Schiffmann3, Raisa S Pompe4, Derya Tilki5, Hans Heinzer6, Markus Graefen6, Pierre I Karakiewicz7, Lars Budäus6.   

Abstract

BACKGROUND: Among prostate cancer (PCa) patients undergoing radical prostatectomy (RP) and with virtually identical unfavorable pathological characteristics, those deemed at low risk (LR) preoperatively had better oncological outcomes than those with intermediate (IR) or high risk (HR) preoperatively.
OBJECTIVE: To examine if this phenomenon still applies when preoperative Cancer of the Prostate Risk Assessment (CAPRA) scores are compared to postoperative scores (CAPRA-S) in RP patients. DESIGN, SETTING, AND PARTICIPANTS: We evaluated 10 290 PCa patients who underwent RP at tertiary care centers in Hamburg (Germany) and Milan (Italy) during 1991-2011. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: All patients were classified as CAPRA/CAPRA-S LR, IR, or HR (≤2, 3-5, and ≥6 points, respectively). Kaplan-Meier and Cox regression analyses were performed to assess the risk of biochemical recurrence (BCR) and metastatic disease (metD). RESULTS AND LIMITATIONS: Overall, 59.6%, 29.3%, and 11.1% patients were CAPRA-S LR, IR, and HR respectively. For CAPRA-S LR patients, 5-yr BCR-free and metD-free rates for preoperative CAPRA LR versus IR/HR patients were 93.1% versus 85.7% (p<0.001) and 99.7% versus 98.9% (p=0.017), respectively. For CAPRA-S IR/HR patients, the corresponding rates were 69.9% versus 57.2% and 98.2 versus 93.7% (both p<0.001). On multivariable Cox regression analyses, a combination of CAPRA-S and preoperative CAPRA resulted in increases in predictive accuracy for BCR (from 76.0% to 78.3%) and metD (from 82.0% to 84.0%). Specifically, biopsy Gleason patterns and the percentage of positive cores added information to the CAPRA-S score. Long-term follow-up is needed to discern clinical metD differences between preoperative CAPRA risk groups.
CONCLUSIONS: CAPRA-S LR patients in the CAPRA IR/HR group had higher BCR/metD risk. Conversely, CAPRA-S IR/HR patients in the CAPRA LR group had lower BCR/metD risk. Future tools should incorporate better tumor and Gleason quantification to optimize prediction. PATIENT
SUMMARY: We demonstrated that among 10290 European patients with prostate cancer who underwent radical prostatectomy, those deemed at low risk preoperatively had better oncological outcomes than their peers with intermediate or high risk, despite virtually identical unfavorable pathological characteristics.
Copyright © 2017 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Biochemical recurrence; Gleason quantification; Gold standard; Metastatic disease; Prediction tool

Mesh:

Year:  2017        PMID: 29129756     DOI: 10.1016/j.euf.2017.10.015

Source DB:  PubMed          Journal:  Eur Urol Focus        ISSN: 2405-4569


  4 in total

1.  Downregulation of serum CXCL4L1 predicts progression and poor prognosis in prostate cancer patients treated by radical prostatectomy.

Authors:  Mo Zhang; Johnny Guan; Yun-Long Huo; Yong-Sheng Song; Li-Zhu Chen
Journal:  Asian J Androl       Date:  2019 Jul-Aug       Impact factor: 3.285

2.  Pre-test 68Ga-PSMA-ligand PET/CT positivity in early biochemical recurrent prostate cancer after radical prostatectomy-validation of a prediction model.

Authors:  Pia Kraft; Tobias Maurer; Andrei Gafita; Markus Krönke; Bernhard Haller; Wolfgang A Weber; Matthias Eiber; Isabel Rauscher
Journal:  EJNMMI Res       Date:  2020-02-03       Impact factor: 3.138

3.  The Dilemma of Misclassification Rates in Senior Patients With Prostate Cancer, Who Were Treated With Robot-Assisted Radical Prostatectomy: Implications for Patient Counseling and Diagnostics.

Authors:  Nikolaos Liakos; Joern H Witt; Pawel Rachubinski; Sami-Ramzi Leyh-Bannurah
Journal:  Front Surg       Date:  2022-02-16

4.  A 38-gene model comprised of key TET2-associated genes shows additive utility to high-risk prostate cancer cases in the prognostication of biochemical recurrence.

Authors:  Shivani Kamdar; Neil E Fleshner; Bharati Bapat
Journal:  BMC Cancer       Date:  2020-10-02       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.